Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
RV

NASDAQ · RVMDW

Revolution Medicines, Inc. Warrant

Healthcare · Biotechnology

$9.64

Down-$0.54 (-5.20%)

Updated Sep 20, 2026, 3:59 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
154.68M
P/E ratio
-15.46
Dividend yield
0.00%
52-week range
$1.53 – $13.44
Volume
63.71K
Avg. volume
28.36K

Price performance

RVMDW price history

1M range · 19 trading sessions · Daily adjusted prices

RVMDW closed at $9.64 after 19 trading sessions, down 19.87% for the selected period.

Last close
$9.64
Period change
-19.87%
Period low
$9.64
Period high
$13.26
Daily close
View OHLC price history
RVMDW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$10.29$10.29$9.50$9.6463.71K
Sep 17, 2026$10.36$11.00$10.20$10.29546K
Sep 16, 2026$10.69$10.95$10.0601$10.4619.68K
Sep 15, 2026$11.45$11.45$11.10$11.306.23K
Sep 14, 2026$11.125$11.50$10.81$11.43543.95K
Sep 11, 2026$10.87$11.299$10.60$11.2914.92K
Sep 10, 2026$11.40$11.40$11.06$11.0614.7K
Sep 9, 2026$11.40$12.249$11.35$11.7146.03K
Sep 8, 2026$11.48$12.15$11.48$11.5823.26K
Sep 4, 2026$11.64$11.89$11.64$11.7038.07K
Sep 3, 2026$11.71$12.09$11.70$11.9823.28K
Sep 2, 2026$11.85$12.16$11.36$11.6227.39K
Sep 1, 2026$11.63$11.81$11.29$11.8120.82K
Aug 31, 2026$11.06$11.50$10.87$11.4621.27K
Aug 28, 2026$13.25$13.35$11.39$11.6442.89K
Aug 27, 2026$13.29$13.44$12.60$13.26157.63K
Aug 26, 2026$11.72$12.80$10.73$12.115184.03K
Aug 25, 2026$12.69$12.869$11.98$11.986.88K
Aug 24, 2026$11.75$12.10$11.34$12.0317.7K

Latest RVMDW news

The latest Smart Investors Daily articles mentioning RVMDW.

Stock researchCompany · Overview

RVMDW research

Overview

Company profile and research snapshot.

Company profile

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 5, 2026

Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval

Revolution Medicines has delivered very large share price gains over the past few years, while broad valuation checks currently suggest the stock leans expensive rather than offering clear value. For investors, the question is how to balance that strong share price history against what the recent valuation signals are implying today. Over the past 5 years, Revolution Medicines has returned about 6x, which sets a high bar for any further upside from here. The recent FDA approval for Rasonque...

Yahoo · Sep 5, 2026

Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal

Revolution Medicines (NasdaqGS:RVMD) reported US FDA approval of RASONQUE for adults with previously treated metastatic pancreatic adenocarcinoma, the first broad RAS targeted therapy for this cancer type. RASONQUE is the first approved therapy from a new class of RAS(ON) multi selective inhibitors aimed at tumors driven by RAS mutations. Phase 1/2 clinical data for RASONQUE in RAS mutant non small cell lung cancer were published in the New England Journal of Medicine, providing independent...

Yahoo · Sep 4, 2026

Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?

Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By